▶ 調査レポート

多血小板血漿(PRP)の世界市場:種類別(純粋PRP、多白血球PRP、純粋多血小板フィブリン、多白血球フィブリン)、由来別(自己、同種異系)、用途別、エンドユーザー別、地域別分析

• 英文タイトル:Global Platelet Rich Plasma Market - Segmented by Type, Source, Application, End-User and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。多血小板血漿(PRP)の世界市場:種類別(純粋PRP、多白血球PRP、純粋多血小板フィブリン、多白血球フィブリン)、由来別(自己、同種異系)、用途別、エンドユーザー別、地域別分析 / Global Platelet Rich Plasma Market - Segmented by Type, Source, Application, End-User and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08456資料のイメージです。• レポートコード:B-MOR-08456
• 出版社/出版日:Mordor Intelligence / 2018年5月15日
• レポート形態:英文、PDF、108ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥450,500 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥477,000 (USD4,500)▷ お問い合わせ
  Corporate User¥927,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、多血小板血漿(PRP)の世界市場について調べ、多血小板血漿(PRP)の世界規模、市場動向、市場環境、種類別(純粋PRP、多白血球PRP、純粋多血小板フィブリン、多白血球フィブリン)分析、由来別(自己、同種異系)分析、用途別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・多血小板血漿(PRP)の世界市場インサイト
・多血小板血漿(PRP)の世界市場環境
・多血小板血漿(PRP)の世界市場動向
・多血小板血漿(PRP)の世界市場規模
・多血小板血漿(PRP)の世界市場規模:種類別(純粋PRP、多白血球PRP、純粋多血小板フィブリン、多白血球フィブリン)
・多血小板血漿(PRP)の世界市場規模:由来別(自己、同種異系)
・多血小板血漿(PRP)の世界市場規模:用途別
・多血小板血漿(PRP)の世界市場規模:エンドユーザー別
・多血小板血漿(PRP)の世界市場:地域別市場規模・分析
・多血小板血漿(PRP)の北米市場規模・予測
・多血小板血漿(PRP)のアメリカ市場規模・予測
・多血小板血漿(PRP)のヨーロッパ市場規模・予測
・多血小板血漿(PRP)のアジア市場規模・予測
・多血小板血漿(PRP)の中国市場規模・予測
・多血小板血漿(PRP)のインド市場規模・予測
・多血小板血漿(PRP)の韓国市場規模・予測
・関連企業情報・競争状況

The platelet-rich plasma market is expected to grow at a CAGR of 14% during the forecast period. Platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.

Prevalence of Arthritis

Osteoarthritis (OA) is the most common form of chronic disorder of the joints, and it has some detrimental effects on the quality of life of the patients. Progressive cartilage destruction, osteophyte formation, and subchondral sclerosis are characteristic to osteoarthritis. Platelet-rich plasma (PRP) is an autologous concentration of a high number of platelets in a small volume of plasma. PRP is prepared centrifuging blood. In knee OA, PRP injections target to promote cartilage repair in order to relieve symptoms of osteoarthritis, hence delaying the need for joint replacement surgery. This will help boost the growth of this market in the forecast period. Along with this, other factors, such as rising incidences of sports injuries, increase in the number of androgenic alopecia patients, and growing use of platelet-rich plasma in various therapeutic areas will also lead to the growth of the market.

High Prices of Plasma Therapy

Plasma-rich platelet therapy, being a relatively new procedure, is generally expensive to undergo. Therefore, patients who have the symptoms might require plasma-rich platelet therapy. Also, as insurance companies consider platelet-rich plasma therapy as an experimental treatment, it is also not covered by them and leads to out-of-pocket expenses, which ends up being costly for the patients. This, along with other factors, such as stringent regulatory policies, will lead to the slowdown of the growth of the market.

North America to Maintain Lead in the Market

North America is expected to dominate the market, followed by Europe. Asia-Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the rising number of osteoarthritis and sports injury cases in this region in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.

Key Developments in the Market:

• November 2017 – The Cascade Medical’s FIBRINET® System designed to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care received FDA approval in the United States.

Major Players: BIO PRODUCT LABORATORY LTD (BPL), BIOLIFE PLASMA SERVICES, BIOTEST, CAMBRYN BIOLOGICS LLC, CHINA BIOLOGIC PRODUCTS, INC., CSL LTD, GRIFOLS INTERNATIONAL S.A., KEDRION S.P.A., LFB SA, AND OCTAPHARMA, amongst others.

Reasons to Purchase the Report

• Current and future platelet rich plasma market in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 month analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Market Dynamics
6.1 Market Drivers
6.1.1 Rising Incidences of Sports Injuries
6.1.2 Increasing Number of Androgenic Alopecia Patients
6.1.3 Growing Use of Platelet-Rich Plasma in Various Therapeutic Areas
6.1.4 Prevalence of Arthritis
6.2 Market Restraints
6.2.1 Stringent Regulatory Policies
6.2.2 High Prices of Plasma Therapy
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Pure PRP
7.1.2 Leukocyte-Rich PRP
7.1.3 Pure Platelet-Rich Fibrin
7.1.4 Leukocyte-Rich Fibrin
7.2 By Source
7.2.1 Autologous
7.2.2 Allogenic
7.3 By Application
7.3.1 Orthopedic
7.3.1.1 Arthritis
7.3.1.2 Chronic Tendinitis
7.3.1.3 Bone Repair & Regeneration
7.3.2 Dermatology
7.3.2.1 Androgenic Alopecia
7.3.2.2 Plastic Surgery
7.3.2.3 Cardiac Muscle Injury
7.3.2.4 Dental
7.3.2.5 Nerve Injury
7.3.2.6 Others
7.4 By End User
7.4.1 Hospitals & Clinics
7.4.2 Research Institutes
7.5 By Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 United Kingdom
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 India
7.5.3.2 Australia & New Zealand
7.5.3.3 South Korea
7.5.3.4 Others
7.5.4 Rest of the World
7.5.4.1 Saudi Arabia
7.5.4.2 Brazil
7.5.4.3 Others
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Bio Product Laboratory Ltd (BPL)
9.2 Biolife Plasma Services
9.3 Biotest
9.4 Cambryn Biologics LLC
9.5 China Biologic Products, Inc.
9.6 CSL Ltd.
9.7 Grifols International S.A.
9.8 Kedrion S.P.A.
9.9 LFB SA
9.10 Octapharma
9.11 List Not Exhaustive
10. Future of the Market